The U.S. FDA halted enrollment in MacroGenics' Phase II trial of lorigerlimab following a patient death and other severe adverse events. The agency's partial hold requires the company to address safety concerns before the study can continue; MacroGenics disclosed the action publicly and indicated cooperation with regulators. The development raises immediate questions about the program's risk profile and timing for any future data readouts or program decisions.